Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Mato

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|March 7, 2022
Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemiaJames Collins, Sarah E Stump, Hillary Heiling, et al.
Leukemia|July 14, 2020
Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisibJennifer R Brown, Andrew Zelenetz, Richard Furman, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2016
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple MyelomaElizabeth Bilotti, David H Vesole, Laura McBride, et al.
American Journal of Hematology|May 2, 2020
Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL expertsBrian Koffman, Anthony Mato, John C Byrd, et al.
Ejhaem|February 23, 2023
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United StatesAnthony Mato, Boxiong Tang, Soraya Azmi, et al.
International Journal of Hematologic Oncology|October 11, 2018
Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNSSarah J Nagle, Nirav N Shah, Alex Ganetsky, et al.
Leukemia & Lymphoma|March 29, 2023
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database studyToby A Eyre, Lisa M Hess, Tomoko Sugihara, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 6, 2014
The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantationMichele L Donato, David S Siegel, David H Vesole, et al.
Leukemia & Lymphoma|February 9, 2018
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect<sup>®</sup> CLL cohort studyChristopher R Flowers, Chadi Nabhan, Neil E Kay, et al.
Leukemia & Lymphoma|March 16, 2013
Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphomaAnthony Mato, Tatyana Feldman, Tania Zielonka, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|March 7, 2022
Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemiaJames Collins, Sarah E Stump, Hillary Heiling, et al.
Leukemia|July 14, 2020
Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisibJennifer R Brown, Andrew Zelenetz, Richard Furman, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2016
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple MyelomaElizabeth Bilotti, David H Vesole, Laura McBride, et al.
American Journal of Hematology|May 2, 2020
Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL expertsBrian Koffman, Anthony Mato, John C Byrd, et al.
Ejhaem|February 23, 2023
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United StatesAnthony Mato, Boxiong Tang, Soraya Azmi, et al.
International Journal of Hematologic Oncology|October 11, 2018
Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNSSarah J Nagle, Nirav N Shah, Alex Ganetsky, et al.
Leukemia & Lymphoma|March 29, 2023
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database studyToby A Eyre, Lisa M Hess, Tomoko Sugihara, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 6, 2014
The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantationMichele L Donato, David S Siegel, David H Vesole, et al.
Leukemia & Lymphoma|February 9, 2018
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect<sup>®</sup> CLL cohort studyChristopher R Flowers, Chadi Nabhan, Neil E Kay, et al.
Leukemia & Lymphoma|March 16, 2013
Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphomaAnthony Mato, Tatyana Feldman, Tania Zielonka, et al.
Pageof 7